Q-omics provides the consensus-scored PRRT1 profile across patient tissues and cancer cell-line models. PRRT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PRRT1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, PRRT1 RNA expression shows 16,778 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where PRRT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRRT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRRT1 survival associations across molecular data types. PRRT1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRRT1 RNA expression–survival associations across cancer types. High PRRT1 expression shows unfavorable associations in COAD, ACC and LUAD, but favorable associations in UVM, PAAD and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PRRT1 RNA expression.
This table summarizes PRRT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRRT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRRT1 shows lower tumor expression in KIRC, KICH, COAD, THCA, LUAD and BRCA. The KIRC box plot shows higher PRRT1 RNA expression in normal versus tumor tissue (log2 FC = −0.598, t-test p < 0.001).
This table shows molecular features associated with PRRT1 in patient tissues and cancer cell lines. In patient samples, PRRT1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRRT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
